Atovaquone
Back to searchMolecule Structure
Scientific Name
Atovaquone
Description of the Drug
Atovaquone is an antimicrobial indicated for the prevention and treatment of Pneumocystis jirovecii pneumonia (PCP) and for the prevention and treatment of Plasmodium falciparum malaria.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01117
http://www.drugbank.ca/drugs/DB01117
Brand Name(s)
Atovaquone, Mepron, Wellvone
Company Owner(s)
Apotex Inc, Padagis Us Llc, Abhai Llc, Abon Pharmaceuticals Llc, Glenmark Generics Ltd, Glaxosmithkline, Hetero Labs Ltd Unit Iii, Amneal Pharmaceuticals, Glenmark Pharmaceuticals Sa, Glaxosmithkline Llc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Cytochrome b | SINGLE PROTEIN | INHIBITOR | CHEMBL1777 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL21694 | |
| Human Metabolome Database | HMDB0015249 | |
| DrugBank | DB01117 | |
| PubChem: Thomson Pharma | 14803776 | |
| Mcule | MCULE-7318126574 | |
| Nikkaji | J389.528I | |
| PDBe | AOQ | |
| EPA CompTox Dashboard | DTXSID7022629 | |
| DrugCentral | 258 | |
| ChemicalBook | CB4383893 | |
| Guide to Pharmacology | 9695 | |
| rxnorm | MEPRON | ATOVAQUONE |
| KEGG Ligand | C06835 | |
| ChEBI | 575568 | |
| ZINC | ZINC000116473771 |
